0.01
0.00%
Close of 9 Nov 2026, in NZD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Truscreen Group
Its shares trade on NZX under the ticker TRU.NZ. It has been listed since 12 November 2014. In the fiscal year to 31 March 2025, it reported revenue of NZD 1.7m and a net loss of NZD 2.2m. At that date it held total assets of NZD 1.8m and shareholders' equity of NZD 1.0m.
TruScreen Group Ltd. engages in the development, manufacture, and sale of cancer detection device and systems. The firm is engaged in the development of an artificial intelligence (AI)-enabled device that can detect precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue. The Company’s cervical screening technology resolves ongoing issues with cytology, including failed samples, poor patient follow-up, patient discomfort, and the need for supporting laboratory infrastructure. The TruScreen device uses opto-electrical technology to evaluate the tissue of the cervix. The TruScreen device consists of a disposable Single Use Sensor (SUS), a Handheld Device (HHD), and an Intelligent Cradle (IC) which works together to detect and identify cancerous and precancerous changes to the cervix. The company also resolves the problems associated with human papillomavirus (HPV) testing, which tests for the much more prevalent HPV virus.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 12 Nov 2014
- Website
- truscreen.com ↗
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- TruScreen Group Ltd develops AI-enabled cervical cancer detection devices for real-time screening.
- The TruScreen device uses opto-electrical technology with disposable Single Use Sensors for accurate tissue evaluation.
- TruScreen resolves issues with cytology including failed samples and poor patient follow-up in cervical screening.
Weaknesses
- The company's cervical screening technology is limited to cervical cancer detection without broader application.
- TruScreen Group Ltd has no established presence in international markets beyond New Zealand.
- The company relies on a single product line for revenue generation and market growth.
Opportunities
- TruScreen's AI-enabled device can expand into HPV testing for broader market reach.
- The global Health Care sector offers opportunities for cervical cancer screening technology adoption.
- New Zealand's Health Care industry supports innovative medical device development.
Threats
- Cervical cancer screening technology faces competition from established medical device companies.
- The Health Care sector is subject to regulatory changes that could impact product approval.
- TruScreen Group Ltd's reliance on a single product line increases market vulnerability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.